SEARCH

SEARCH BY CITATION

References

  • Argyrou A, Vetting MW, Aladegbami B & Blanchard JS (2006) Mycobacterium tuberculosis dihydrofolate reductase is a target for isoniazid. Nature Structural & Molecular Biology 13, 408413. Epub 2006 Apr 30.
  • Balasubramanian V, Wiegeshaus EH, Taylor BT & Smith DW (1994) Pathogenesis of tuberculosis: pathway to apical localization. Tubercle and Lung Disease 75, 168178.
  • Behar SM, Divangahi M & Renold HG (2010) Evasion of innate immunity by Mycobacterium tuberculosis: is death an exit strategy? Nature Reviews Microbiology 8, 668674.
  • Biketov S, Potapov V, Ganina E, Downing K, Kana BD & Kaprelyants A (2007) The role of resuscitation promoting factors in pathogenesis and reactivation of Mycobacterium tuberculosis during intra-peritoneal infection in mice. BMC Infectious Diseases 7, 146.
  • Corbett EL, Watt CJ, Walker N, Maher D, Williams BG, Raviglione MC & Dye C (2003) The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Archives of Internal Medicine 163, 10091021.
  • Ehlers S (2009) Lazy dynamic or minimally recrudescent? On the elusive nature and location of the mycobacterium responsible for latent tuberculosis. Infection 37, 8795.
  • Fraser A, Paul M, Attamna A & Leibovici L (2006) Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. International Journal of Tuberculosis and Lung Disease 10, 1923.
  • Grange JM (1992) The mystery of the mycobacterial persistor. Tubercle and Lung Disease 73, 249251.
  • Henderson B, Lund PA & Coates AR (2010) Multiple moonlighting functions of mycobacterial molecular chaperones. Tuberculosis (Edinb) 90(2), 119124.
  • Hernández-Pando R, Jeyanathan M, Mengistu G, Aguilar D, Orozco H, Harboe M, Rook GA & Bjune G (2000) Persistence of DNA from Mycobacterium tuberculosis in superficially normal lung tissue during latent infection. Lancet 356, 21332138.
  • Honaker RW, Leistikow RL, Bartek IL & Voskuil MI (2009) Unique roles of DosT and DosS in DosR regulon induction and Mycobacterium tuberculosis dormancy. Infection and Immunity 77, 32583263.
  • Kang CM, Nyayapathy S, Lee JY, Suh JW & Husson RN (2008) Wag31, a homologue of the cell division protein DivIVA, regulates growth, morphology and polar cell wall synthesis in mycobacteria. Microbiology 154(Pt 3), 725735.
  • Lin MY & Ottenhoff TH (2008) Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention. Endocrine Metabolic & Immune Disorders – Drug Targets 8, 1529.
  • Lobue P & Menzies D (2010) Treatment of latent tuberculosis infection: An update. Respirology 15(4), 603622.
  • Mack U, Migliori GB, Sester M, et al. (2009) LTBI: latent tuberculosis infection or lasting immune responses to M.tuberculosis? A TBNET consensus statement. European Respiratory Journal 33, 956973.
  • Marais BJ, Ayles H, Graham S & Godfrey-Faussett P (2009) Screening and preventive therapy for tuberculosis. Clinics in Chest Medicine 30, 827846.
  • Migliori GB, Dheda K, Centis R, Mwaba P, Bates M, O’Grady J, Hoelscher M & Zumla A (2010) Review of multidrug-resistant and extensively drug-resistant TB: global perspectives with a focus on sub-Saharan Africa. Tropical Medicine and International Health 15, 10521066.
  • Mitchison DA (1985) The action of antituberculosis drugs in short-course chemotherapy. Tubercle 66, 219225.
  • Neyrolles O, Hernández-Pando R, Pietri-Rouxel F, Fornès P, Tailleux L, Barrios Payán JA, Pivert E, Bordat Y, Aguilar D, Prévost MC, Petit C & Gicquel B (2006) Is adipose tissue a place for Mycobacterium tuberculosis persistence? PLoS One 1, e43.
  • Opie EL & Aronson JD (1927) Tubercle bacilli in latent tuberculosis lesions and in lung tissue without tuberculous lesions. Archives of Pathology & Laboratory Medicine 4, 121.
  • Parris NM, Dick JD & Bishai WR (1998) Mechanisms of latency in Mycobacterium tuberculosis. Trends in Microbiology 6(3), 107112.
  • Sterling TR (2008) New approaches to the treatment of latent tuberculosis. Seminars in Respiratory and Critical Care Medicine 29, 532541.
  • Stanford JL (1987) Much’s granules revisited. Tubercle 68, 241242.
  • Sudre P, ten Dam G & Kochi A (1992) Tuberculosis: a global overview of the situation today. Bulletin WHO 70(2), 149159.
  • Timmins GS, Master S, Rusnak F & Deretic V (2004) Nitric oxide generated from isoniazid activation by KatG: source of nitric oxide and activity against Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy 48, 30063009.
  • Vilchèze C & Jacobs WR Jr (2007) The mechanism of isoniazid killing: clarity through the scope of genetics. Annual Reviews of Microbiology 61, 3550.
  • WHO Report (1998) Policy Statement on Preventive Therapy Against Tuberculosis in People Living with HIV. WHO/TB/98.255, World Health Organization, Geneva.
  • WHO (2010) M/XDR-TB Surveillance and Control: 2010 Global Update. Geneva, Switzerland. Report WHO/HTM/TB. World Health Organization, Geneva.